Publications by authors named "D E Sabatino"
Modulation of AAV transduction and integration targeting by topoisomerase poisons.
Mol Ther Methods Clin Dev
December 2024
Adeno-associated virus (AAV) is a widely used vehicle for gene delivery, lending interest to developing methods for enhancing AAV transduction and transgene expression. Here, we profile the function of several topoisomerase poisons, which are small molecules that stabilize topoisomerase enzymatic intermediates, where topoisomerase enzymes are covalently bound at chromosomal DNA breaks. As previously observed, we found that the topoisomerase poisons camptothecin (CPT), doxorubicin (DOX), and etoposide (ETO) increased AAV transduction in cultured cell models.
View Article and Find Full Text PDFValidation of a molecular multiplex assay for the simultaneous detection and differentiation of bluetongue virus and epizootic haemorrhagic disease virus in biological samples.
J Virol Methods
February 2025
Article Synopsis
- Bluetongue virus (BTV) and epizootic haemorrhagic disease virus (EHDV) are viruses spread by biting midges that cause serious diseases in ruminants, and they circulate in different forms (serotypes).
- A new EHDV strain (serotype 8) was first found in Tunisia in 2021 and later identified in cattle in Italy, Spain, Portugal, and France in 2022, where BTV is already a concern.
- Researchers developed a TaqMan RT-qPCR assay that efficiently detects and differentiates BTV and EHDV, providing a quick and cost-effective method for diagnosis, aiding in better surveillance and control of these diseases.
The expansive field of drug discovery is continually seeking innovative approaches to identify and develop novel peptide-based therapeutics. With the advent of artificial intelligence (AI), there has been a transformative shift in the generation of new peptide drugs. AI offers a range of computational tools and algorithms that enables researchers to accelerate the therapeutic peptide pipeline.
View Article and Find Full Text PDFArticle Synopsis
- Regulators and industry experts are looking for better ways to assess the cancer-causing potential of gene therapies, as current methods may not be sufficient.
- A meeting in London in March 2023 brought together specialists to reach a consensus on key themes such as vector genotoxicity, uncertainty sources, and appropriate toxicological endpoints for gene therapy evaluation.
- The recommendations from this meeting aim to guide the creation of new regulatory guidelines for the nonclinical toxicological assessment of gene therapy products.